Search results for "acute lymphocytic leukemia"

showing 8 items of 28 documents

Patient with Kabuki syndrome and acute leukemia

2003

Kabuki syndrome is a multiple congenital anomaly/mental retardation syndrome which often involves recurrent infections. There is cumulative evidence of an immunodeficiency in Kabuki patients. We report a 2-year-old girl with typical Kabuki syndrome, who developed acute lymphocytic leukemia. The patient showed low levels of immunoglobulins G and A and a history of recurrent infections, that might indicate an immunodeficiency leading to an increased susceptibility to cancer. The girl was treated according to BFM protocols adapted to the patient's impaired cardiac situation and severe underweight. She achieved continual complete remission. Classical and molecular cytogenetic analyzes did not d…

Pediatricsmedicine.medical_specialtyAcute leukemiabusiness.industryKabukiInfantCancerPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseIntellectual DisabilityImmunopathologyAcute lymphocytic leukemiaImmunologymedicineHumansAbnormalities MultipleFemaleAbnormalitybusinessKabuki syndromeGenetics (clinical)ImmunodeficiencyAmerican Journal of Medical Genetics
researchProduct

Transcriptional regulation of the stem cell leukemia gene by PU.1 and Elf-1.

1998

Abstract The SCL gene, also known astal-1, encodes a basic helix-loop-helix transcription factor that is pivotal for the normal development of all hematopoietic lineages. SCL is expressed in committed erythroid, mast, and megakaryocytic cells as well as in hematopoietic stem cells. Nothing is known about the regulation of SCL transcription in mast cells, and in other lineages GATA-1 is the only tissue-specific transcription factor recognized to regulate the SCL gene. We have therefore analyzed the molecular mechanisms underlyingSCL expression in mast cells. In this paper, we demonstrate that SCL promoter 1a was regulated by GATA-1 together with Sp1 and Sp3 in a manner similar to the situati…

Transcription GeneticDNA FootprintingBiologyBiochemistryCell LineMiceTranscription (biology)hemic and lymphatic diseasesProto-Oncogene ProteinsmedicineTranscriptional regulationBasic Helix-Loop-Helix Transcription FactorsAnimalsMast CellsPromoter Regions GeneticMolecular BiologyTranscription factorT-Cell Acute Lymphocytic Leukemia Protein 1DNA PrimersBase SequenceGATA2Nuclear ProteinsGATA1Cell BiologyMast cellMolecular biologyDNA-Binding ProteinsHaematopoiesismedicine.anatomical_structureGene Expression RegulationMutagenesis Site-DirectedTrans-ActivatorsStem cellTranscription FactorsThe Journal of biological chemistry
researchProduct

Distinct 5' SCL enhancers direct transcription to developing brain, spinal cord, and endothelium: neural expression is mediated by GATA factor bindin…

1999

The SCL gene encodes a basic helix-loop-helix transcription factor with a pivotal role in the development of endothelium and of all hematopoietic lineages. SCL is also expressed in the central nervous system, although its expression pattern has not been examined in detail and its function in neural development is unknown. In this article we present the first analysis of SCL transcriptional regulation in vivo. We have identified three spatially distinct regulatory modules, each of which was both necessary and sufficient to direct reporter gene expression in vivo to three different regions within the normal SCL expression domain, namely, developing endothelium, midbrain, and hindbrain/spinal …

animal structuresEmbryo NonmammalianTranscription GeneticHindbrainMice TransgenicChick EmbryoBiologybehavioral disciplines and activities03 medical and health sciencesMice0302 clinical medicineTranscription (biology)Genes Reporterhemic and lymphatic diseasesProto-Oncogene ProteinsBasic Helix-Loop-Helix Transcription FactorsAnimalsTissue DistributionEndotheliumEnhancerMolecular BiologyTranscription factorGeneIn Situ HybridizationT-Cell Acute Lymphocytic Leukemia Protein 1Zebrafish030304 developmental biologyRegulation of gene expressionGenetics0303 health sciencesReporter geneModels GeneticfungiBrainCell BiologyZebrafish ProteinsEmbryo MammalianCell biologyDNA-Binding ProteinsLac OperonSpinal CordNeural development030217 neurology & neurosurgeryDevelopmental BiologyTranscription FactorsDevelopmental biology
researchProduct

Detection of Immunoglobulin Heavy Chain Gene Clonality By High-Throughput Sequencing for Minimal Residual Disease Monitoring in Chronic Lymphocytic L…

2019

Introduction: The negative minimal residual disease (MRD) after treatment has been recently accepted as endpoint for Chronic Lymphocytic Leukaemia (CLL) clinical trials. Conventionally, MRD can be detected by using multi-color Flow Cytometry (FC) with high sensitivity. Determination of the clonal immunoglobulin gene rearrangement can be a useful monitoring marker in a broad range of B-cell lymphoproliferative neoplasms. Moreover, the mutational status of immunoglobulin heavy chain variable (IgHV) rearrangement is considered one of the most important prognostic factors in CLL. Therefore, the identification of the IgHV rearrangement can be a useful marker both at diagnostic and as monitoring …

clone (Java method)Chronic lymphocytic leukemiaImmunologyCell BiologyHematologyComputational biologyBiologymedicine.diseaseBiochemistryMinimal residual diseasegenomic DNAEuroFlowhemic and lymphatic diseasesAcute lymphocytic leukemiamedicineMultiplexIGHV@Blood
researchProduct

Salvage Therapy of Adult ALL

1996

In a first study (1986 to 1992) the German Relapsing ALL Study Group (GRALLSG) has treated 67 adult patients with a first relapse of ALL. A first phase of induction consisted of vindesine, daunorubicin, asparaginase, and prednisone, a second phase of high-dose cytosine-arabinoside (Hd ara-C) and VP16. Results: 45 CR, 2 PR, 13 failures, 7 early death. 25 patients received a BMT. 10 had an allogeneic BMT in CR, 5 after another relapse or with refractory disease. Of 10 with autologous BMT 8 have been in 2nd CR. Only 4 of all 67 patients are surviving without relapse: One after unrelated BMT (36+mo), two after autologous BMT in 2nd CR (46+, 64+mo), and one after chemotherapy (61+mo). One patien…

medicine.medical_specialtyChemotherapyIfosfamidebusiness.industrymedicine.medical_treatmentSalvage therapymedicine.diseaseGastroenterologyPrednisoneAcute lymphocytic leukemiaInternal medicinemedicinePrednisoloneVindesineIdarubicinbusinessmedicine.drug
researchProduct

A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood ‘high-risk’ acute lymphoblastic leukaemia:…

2002

The outcome of children with acute lymphoblastic leukaemia (ALL) and early relapse remains unsatisfactory. In January 1995, the AIEOP (Associazione Italiana di Oncologia ed Ematologia Pediatrica) group opened a trial for children with ALL in first isolated or combined bone marrow relapse defined at high risk according to the length of first remission and the immunophenotype. The treatment plan included the combination of a single high-dose idarubicin and high-dose cytarabine as induction therapy followed by an intensive consolidation and stem cell transplant (SCT). In total, 100 children from 16 Italian centres were enrolled; 80 out of the 99 evaluable patients (81%) achieved second complet…

medicine.medical_specialtyChemotherapybusiness.industrymedicine.drug_classmedicine.medical_treatmentHematologyHematopoietic stem cell transplantationmedicine.diseaseAntimetaboliteSurgerymedicine.anatomical_structureInternal medicineAcute lymphocytic leukemiaCytarabineMedicineIdarubicinBone marrowbusinessSurvival ratemedicine.drugBritish Journal of Haematology
researchProduct

Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults

1988

Abstract Thirty-six patients with relapsed acute lymphoblastic leukemia (ALL) and four with primary refractory ALL were treated with a regimen that included amsacrine, 200 mg/m2, intravenously daily for three days with cytarabine, 3 gm/m2, by infusion over three hours daily for five days. There were 27 remissions in the 36 relapsed patients and two in the four patients with primary refractory disease. Seventeen of the 23 patients with common ALL, four of the six with T-cell ALL, one of the three with B-cell ALL, and seven of eight whose cells were not characterized responded. Toxicity of this regimen was comparable to other reinduction regimens for ALL, but the side effects characteristic o…

medicine.medical_specialtyChemotherapymedicine.drug_classbusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologymedicine.diseaseBiochemistryAntimetaboliteGastroenterologySurgeryRegimenRefractoryAcute lymphocytic leukemiaInternal medicineToxicitymedicineCytarabinebusinessAmsacrinemedicine.drugBlood
researchProduct

The Pro-Inflammatory IL23/IL23R/IL17 Axis Is Active in IL23R-Expressing Circulating CLL Cells in Patients with Poor Prognosis

2012

Abstract Abstract 3889 Inflammatory cytokines play a biological role in the pathogenesis of Chronic lymphocytic leukemia (CLL). IL23 is a pro-inflammatory cytokine involved in T-cell responses and in tissue remodeling. It has been shown that the IL23 receptor (IL23R) is up-regulated in primary acute lymphoblastic leukemia (ALL) cells, and that IL23 inhibits ALL cell growth. Nevertheless, the anti-tumor function of IL23 still remains controversial. The role of the IL23R/IL23 axis in CLL has not been investigated so far. Herein we evaluated the expression pattern of IL23R/IL23 axis and its correlation with progression free survival (PFS) in CLL patients. A total of 233 newly diagnosed Binet s…

musculoskeletal diseasesPathologymedicine.medical_specialtyChronic lymphocytic leukemiaImmunologyContext (language use)Cell BiologyHematologyCD38Biologymedicine.diseaseBiochemistrymedicine.anatomical_structureAcute lymphocytic leukemiamedicineImmunohistochemistryBone marrowProgression-free survivalLymph nodeBlood
researchProduct